The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses oncology targeting biosimilars that are nearing approval
Published: 04 May 2017
Ted Okon, MBA, regarding the key issues faced by community oncologists today
Ted Okon, MBA, Executive Director, Community Oncology Alliance, discusses the key issues faced by community oncologists today
Ted Okon, MBA, on what COA is doing to help community oncology practices
Ted Okon, MBA, Executive Director, Community Oncology Alliance, elaborates on what COA is doing to help community oncology practices
Ted Okon, MBA, considers what can be done to encourage PBM transparency
Ted Okon, MBA, Executive Director, Community Oncology Alliance, tells us what can be done to encourage transparency at PBMs
Nate Brown offers opinion on whether practices in a MIPS track should consider moving to an APM
Nate Brown, Senior Product Marketing Manager, Flatiron Health, on whether practices already in a MIPS track should consider moving to ...
Robert Rifkin, MD, on the hurdles that might prevent adoption of biosimilars by oncologists
Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, speculates on what might influence the adoption of biosimilars by oncologists
Mark Fendrick, MD, considers the challenges associated with value-based insurance design
Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, discusses the challenges associated with value-based insurance design when applied to ...
Ray Page, DO, PhD, explains cancer patient advocacy & how it enhances the delivery of cancer care
Dr. Page, President & Director of Research, The Center for Cancer & Blood Disorders, discusses cancer patient advocacy and the ...
Robert Rifkin, MD, lists those biosimilars now approved or close to approval
Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, shares which biosimilars are currently approved or close to approval for ...
Mark Fendrick, MD, on designing incentives when dealing with expensive cancer therapies
Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, elaborates on whether newer, more expensive cancer therapies impact value-based insurance ...
Ray Page, DO, PhD, on what oncology practices should be doing to advocate for their patients
Dr. Page, President & Director of Research, The Center for Cancer & Blood Disorders, offers opinion on what everyday oncology ...
